News Image

Boundless Bio Announces Pipeline and Leadership Updates

Provided By GlobeNewswire

Last update: Dec 12, 2024

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial

Third ecDTx program advancing, with plans for development candidate nomination by mid-2025

Read more at globenewswire.com

BOUNDLESS BIO INC

NASDAQ:BOLD (7/30/2025, 8:00:02 PM)

After market: 1.19 0 (0%)

1.19

0 (0%)



Find more stocks in the Stock Screener

Follow ChartMill for more